Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection

被引:114
作者
Kimura, H
Hoshino, Y
Hara, S
Sugaya, N
Kawada, J
Shibata, Y
Kojima, S
Nagasaka, T
Kuzushima, K
Morishima, T
机构
[1] Nagoya Univ, Grad Sch Med, Dept Pediat, Showa Ku, Nagoya, Aichi 4668550, Japan
[2] Nagoya Univ, Grad Sch Med, Dept Clin Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan
[3] Nagoya Univ, Sch Hlth Sci, Dept Nursing, Nagoya, Aichi, Japan
[4] Aichi Canc Ctr, Res Inst, Div Immunol, Nagoya, Aichi 464, Japan
基金
日本学术振兴会;
关键词
D O I
10.1086/427239
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Infections of T cells and natural killer (NK) cells play a central role in the pathogenesis of chronic active Epstein-Barr virus (CAEBV) infection. To characterize the virologic and cytokine profiles of T cell-type and NK cell-type infection, 39 patients with CAEBV infection were analyzed. Patients with T cell-type infection had higher titers of immunoglobulin G against early and late EBV antigens, suggesting lytic cycle infection. However, the pattern of EBV gene expression was latency type II; BZLF1, which is a hallmark of lytic cycle infection, could not be detected in any patients, regardless of infection type. Patients with CAEBV infection had high concentrations of proinflammatory, T helper cell type 1, and anti-inflammatory cytokines. The cytokine profile in patients with NK cell-type infection was similar to that in patients with T cell-type infection, but the concentration of IL-13 was high in patients with NK cell-type infection. These findings should help to clarify the pathogenesis of CAEBV infection and facilitate the development of more-effective treatments.
引用
收藏
页码:531 / 539
页数:9
相关论文
共 55 条
[1]  
ALFIERI C, 1984, CAN MED ASSOC J, V131, P1249
[2]  
Cabrerizo M, 1997, J AM SOC NEPHROL, V8, P1443
[3]   A SUBPOPULATION OF NORMAL B-CELLS LATENTLY INFECTED WITH EPSTEIN-BARR-VIRUS RESEMBLES BURKITT-LYMPHOMA CELLS IN EXPRESSING EBNA-1 BUT NOT EBNA-2 OR LMP1 [J].
CHEN, F ;
ZOU, JZ ;
DIRENZO, L ;
WINBERG, G ;
HU, LF ;
KLEIN, E ;
KLEIN, G ;
ERNBERG, I .
JOURNAL OF VIROLOGY, 1995, 69 (06) :3752-3758
[4]   Epstein-Barr virus infection. [J].
Cohen, JI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) :481-492
[5]   Interleukin-13 levels in serum from patients with Hodgkin disease and healthy volunteers [J].
Fiumara, P ;
Cabanillas, F ;
Younes, A .
BLOOD, 2001, 98 (09) :2877-2878
[6]   An overview of real-time quantitative PCR: Applications to quantify cytokine gene expression [J].
Giulietti, A ;
Overbergh, L ;
Valckx, D ;
Decallonne, B ;
Bouillon, R ;
Mathieu, C .
METHODS, 2001, 25 (04) :386-401
[7]   Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies [J].
Gottschalk, S ;
Edwards, OL ;
Sili, U ;
Huls, MH ;
Goltsova, T ;
Davis, AR ;
Heslop, HE ;
Rooney, CM .
BLOOD, 2003, 101 (05) :1905-1912
[8]   Prospective monitoring of the Epstein-Barr virus DNA by a real-time quantitative polymerase chain reaction after allogenic stem cell transplantation [J].
Hoshino, Y ;
Kimura, H ;
Tanaka, N ;
Tsuge, I ;
Kudo, K ;
Horibe, K ;
Kato, K ;
Matsuyama, T ;
Kikuta, A ;
Kojima, S ;
Morishima, T .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :105-111
[9]   Epstein-Barr virus (EBV)-carrying and -expressing T-cell lines established from severe chronic active EBV infection [J].
Imai, S ;
Sugiura, M ;
Oikawa, O ;
Koizumi, S ;
Hirao, M ;
Kimura, H ;
Hayashibara, H ;
Terai, N ;
Tsutsumi, H ;
Oda, T ;
Chiba, S ;
Osato, T .
BLOOD, 1996, 87 (04) :1446-1457
[10]  
Ito Y, 1999, J MED VIROL, V58, P420, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt